Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M10,846Revenue $M895Net Margin (%)-34.7Altman Z-Score5.2
Enterprise Value $M10,888EPS $-2.0Operating Margin %-30.3Piotroski F-Score2
P/E(ttm)--Beneish M-Score-2.2Pre-tax Margin (%)-35.0Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %--Quick Ratio2.3Cash flow > EarningsY
Price/Sales11.85-y EBITDA Growth Rate %--Current Ratio3.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-9.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-15.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M161ROIC % (ttm)-14.0Gross Margin Increase y-yN

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNJoel Greenblatt 2015-06-30 Sold Out $112.05 - $140
($123.93)
$ 67.26-46%Sold Out0
BMRNJoel Greenblatt 2015-03-31 Buy $90.28 - $129.14
($105.95)
$ 67.26-37%New holding4,195
BMRNJoel Greenblatt 2014-12-31 Sold Out $67.27 - $94.19
($83.42)
$ 67.26-19%Sold Out0
BMRNJoel Greenblatt 2014-09-30 Buy $55.78 - $73
($65.82)
$ 67.262%New holding3,885
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 67.268%Sold Out0
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 67.2619%Reduce -69.03%40,700
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 67.2648%Reduce -60.99%131,400
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 67.2687%Sold Out0
BMRNGeorge Soros 2012-03-31 Add0.11%$33.68 - $38.34
($32.99)
$ 67.26104%Add 300.00%300,000
BMRNGeorge Soros 2011-12-31 Reduce-0.05%$30.07 - $35.38
($32.81)
$ 67.26105%Reduce -57.14%75,000
BMRNGeorge Soros 2011-06-30 Add0.07%$24.93 - $28.455
($26.32)
$ 67.26156%Add 862.36%191,510
BMRNMeridian Funds 2011-03-31 Reduce-0.28%$23.46 - $28.29
($25.46)
$ 67.26164%Reduce -51.54%348,800
BMRNGeorge Soros 2011-03-31 Buy 0.01%$23.46 - $28.29
($25.46)
$ 67.26164%New holding19,900
BMRNGeorge Soros 2010-09-30 Sold Out -0.02%$18.24 - $23.09
($20.93)
$ 67.26221%Sold Out0
BMRNMeridian Funds 2010-03-31 Add0.13%$18.75 - $23.81
($20.92)
$ 67.26222%Add 20.83%795,900
BMRNGeorge Soros 2010-03-31 Add$18.75 - $23.81
($20.92)
$ 67.26222%Add 35.87%30,300
BMRNGeorge Soros 2009-12-31 Buy 0.01%$15.49 - $18.98
($17.17)
$ 67.26292%New holding22,300
BMRNMeridian Funds 2009-09-30 Buy 0.53%$13.86 - $18.33
($15.84)
$ 67.26325%New holding658,700
BMRNBill Gates 2009-06-30 Sold Out -0.02%$11.92 - $15.94
($13.79)
$ 67.26388%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Davis George EricSVP, General Counsel 2015-12-16Sell1,362$100-32.98view
BIENAIME JEAN JACQUESCEO 2015-11-30Sell1,000$94.74-29.26view
LAWLIS V BRYANDirector 2015-11-16Sell8,550$106.9-37.31view
GREY MICHAEL GDirector 2015-11-16Sell7,500$104.27-35.72view
SPIEGELMAN DANIEL KEVP, CFO 2015-11-16Sell20,000$104.3-35.74view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-11-02Sell26$117.56-42.99view
BIENAIME JEAN JACQUESCEO 2015-10-15Sell1,000$108.24-38.08view
BIENAIME JEAN JACQUESCEO 2015-09-14Sell1,000$131.43-49.01view
BIENAIME JEAN JACQUESCEO 2015-08-12Sell1,500$134.72-50.25view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-07-20Sell3,000$150-55.32view

Press Releases about BMRN :

Quarterly/Annual Reports about BMRN:

    News about BMRN:

    Articles On GuruFocus.com
    J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
    WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
    BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 

    More From Other Websites
    BioMarin Pharmaceutical's Illness Could Be Cured Feb 08 2016
    It’s Time to Buy This Biotech Gem Feb 04 2016
    Headline Risk Is Poison for Pharma and Biotech Feb 03 2016
    Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics,... Feb 01 2016
    BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on... Jan 28 2016
    BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on... Jan 28 2016
    Changes in BioMarin’s Valuation Multiples Jan 26 2016
    Duchenne drug by Cambridge's Catabasis looks safe in early trial Jan 25 2016
    Snowstorm Dashes Hopes for Sarepta Drug's Dystrophy Patients Jan 22 2016
    The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug Jan 21 2016
    Muscular Dystrophy Drugs Face New FDA Questions Jan 20 2016
    Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie Jan 20 2016
    Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus Jan 20 2016
    10 Biotech Buys from Credit Suisse Jan 20 2016
    Coverage initiated on Biomarin Pharm by Credit Suisse Jan 20 2016
    What Are the Potential Drivers of BioMarin? Jan 19 2016
    What Are Analysts’ Expectations for BioMarin? Jan 19 2016
    ​Science, and not patients, will turn the tide for Sarepta's Duchenne drug Jan 19 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK